Status:

COMPLETED

F-18-Fluorocholine PET/CT and MR Imaging/ Spectroscopy in the Management of Primary and Recurrent Prostate Cancer

Lead Sponsor:

University of Lausanne Hospitals

Collaborating Sponsors:

Advanced Accelerator Applications

Conditions:

Prostate Cancer

Eligibility:

MALE

Up to 80 years

Brief Summary

The purpose of this study is to demonstrate that realization of guided biopsies by multimodal imaging with 18F-fluorocholine PET / CT and MR Imaging/spectroscopy would allow to increase the rate of de...

Detailed Description

1. To evaluate the utility of F-18-FCH-PET/CT and MR imaging with 3-D MR spectroscopy in detecting, localizing, and estimating the volume of initial primary prostate cancer as compared to the current ...

Eligibility Criteria

Inclusion

  • PRIMARY PROSTATE CANCER
  • Age ≤ 80 years
  • Karnofsky index ≥ 80
  • First prostate biopsy
  • Presence of at least one of the following:
  • Total PSA 10 ng/mL
  • Total PSA 2.5-10 ng/mL with free-PSA \<20% and/or PSA velocity 0.75 ng/mL/year
  • Suspicious hypoechoic lesion at TRUS and/or suspicious finding at digital rec¬tal examination
  • Informed signed consent.

Exclusion

  • Impaired capacity to consent
  • Coexistence of clinically-proven prostate cancer
  • Neoadjuvant hormonal treatment (including 5-α reductase inhibitors)
  • Contraindications to surgery
  • Contraindications to MR Imaging (see below)
  • PROSTATE CANCER RELAPSE
  • Inclusion Criteria:
  • Age ≤ 90 years
  • Karnofsky index ≥ 80
  • Previous treatment for prostate cancer
  • No clinical recurrence based on standard work-up (abdominal / pelvic CT, MRI, and bone scintigraphy)
  • Biochemically proven relapse of prostate cancer (PSA \> 0.2 ng/mL after prostatectomy, nadir PSA+2 ng/mL (Phoenix definition) or ≤ 3 successive rising PSA levels (ASTRO definition) after curative radiotherapy).
  • Informed signed consent.

Key Trial Info

Start Date :

August 1 2009

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

January 1 2018

Estimated Enrollment :

60 Patients enrolled

Trial Details

Trial ID

NCT00963755

Start Date

August 1 2009

End Date

January 1 2018

Last Update

July 26 2021

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Centre Hospitalier Universitaire Vaudois

Lausanne, CH, Switzerland, 1011